Updated:
Frazier Life Sciences
Frazier Life Sciences operates from Palo Alto with additional offices in San Diego, Boston, and Seattle, deploying capital across two distinct but...
Frazier Life Sciences
Frazier Life Sciences operates from Palo Alto with additional offices in San Diego, Boston, and Seattle, deploying capital across two distinct but coordinated strategies. The venture arm manages over $4 billion, concentrating on company creation and Series A financings for early-stage biopharmaceuticals. The public equity arm runs a long-only, evergreen pool exceeding $2.8 billion, targeting small- and mid-cap public biotechs and selected crossover rounds. The firm's 25-plus companies created since 2015, alongside more than 50 IPOs and M&A events representing over $75 billion in cumulative transaction value, demonstrate a model that builds and scales therapeutics companies from inception through approval. Confirmed positions include academy spinout Radionetics Oncology, where the venture team co-led the 2021 creation alongside 5AM Ventures and Crinetics, followed by a 2024 strategic agreement with Lilly that included a $140 million upfront payment and a $1 billion acquisition option. The public funds team invested in Krystal Biotech as the sole participant in a 2018 PIPE shortly after its IPO, then supported it through a 2022 ATM financing and a subsequent commercial-launch PIPE. Alpine Immune Sciences illustrates cross-fund synergy: the venture arm co-led its 2016 Series A, and the public team led a fall 2021 PIPE, with Vertex acquiring the company in 2024 for $4.9 billion. The footprint concentrates on North America and Europe, with select investments in Asia. July 2025: Frazier Life Sciences closed an oversubscribed $1.3 billion venture fund, its largest to date (per the firm, July 2025). The firm lists Managing Partner Jamie Topper and General Partners including a public-portfolio manager, but does not publish a full headcount. Adjacent activities include operating advisors embedded in portfolio companies, though no separate philanthropic foundation or club-membership structures are disclosed. Frazier's structural distinction lies in running an in-house crossover engine: the public fund can inject later-stage capital into venture-backed companies without requiring external syndication at critical inflection points, creating a financing continuum that few dedicated biotech platforms replicate. This internal pipeline effectively marries the firm's company-creation pipeline to its own public-markets distribution, reducing reliance on outside crossover investors.
General information
Firm type
Multi Family Office
Year founded
—
AUM
$6.9B (Altss estimate)
Location
Region
North America
Country
United States
City
Palo Alto
Corporate office
Palo Alto, CA, United States
Additional offices
San Diego, CA · Boston, MA · Seattle, WA
Principals
Jamie Topper
Managing Partner
Sector focus
Frequently asked questions
How does Frazier Life Sciences manage the transition from private to public financing?
The firm operates coordinated venture and public equity strategies. The venture arm builds companies around early-stage assets, typically co-leading Series A rounds. The public equity team, running a long-only pool, then evaluates those same companies for crossover investments, PIPEs, or follow-on public-market purchases, providing capital continuity and reducing reliance on external public investors.
Does Frazier create new biotech companies or primarily back existing ones?
Company creation is central to the venture strategy. Since 2015, the firm has created over 25 companies by founding or co-founding entities around licensed academic technology or corporate spinouts, often working with co-investors such as 5AM Ventures and DCVC. Radionetics Oncology, co-created with 5AM and Crinetics in 2021, is one example.
What is the public equity strategy's investment mandate?
The public equity strategy is a long-only, evergreen vehicle targeting publicly traded small- and mid-cap biopharmaceutical companies and private crossover rounds. It can take concentrated positions, serve as a sole investor in PIPEs as it did for Krystal Biotech in 2018, and maintain holdings through commercialization and FDA approval.
How is the firm's leadership structured?
Jamie Topper serves as Managing Partner. The firm lists additional General Partners dedicated to venture, company creation, and public portfolio management, though it does not disclose a full partnership roster. Operating advisors and senior advisors provide scientific and operational support to portfolio companies but are not employees of the firm.
What is Frazier Life Sciences' relationship to the broader Frazier organization?
Frazier Life Sciences operates as a dedicated biotechnology and therapeutics investment platform. It is a separate entity from Frazier Healthcare Partners, which historically invested across healthcare services and therapeutics before spinning out or separating its life sciences activities into the current firm structure.
Which fund structures does Frazier use for venture investments?
The venture strategy raises closed-end funds. Its most recent vehicle closed in July 2025 at $1.3 billion, oversubscribed (per the firm, July 2025). These funds invest in company creation, Series A rounds, and follow-on private financings.
Does Frazier Life Sciences hold companies through their commercial stage?
Yes. The public equity strategy frequently supports portfolio companies through commercialization. With Krystal Biotech, for example, the public team invested pre-FDA approval and participated in a subsequent PIPE to fund the commercial launch of Vyjuvek for dystrophic epidermolysis bullosa.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: